Advertisement
MIAMI, May 3, 2019 /PRNewswire-PRWeb/ -- Bio-Tissue, Inc., a TissueTech, Inc. company and the market leader in the clinical application of cryopreserved amniotic membrane-based products for the treatment of diseases and disorders of the ocular surface, today announced that Mark S. Milner, M.D., FACS, Associate Clinical Professor at Yale University Medical School and Co-founder and Co-medical Director of Precision LASIK Group, will present about his use of Cryopreserved Amniotic Membrane to Treat Ocular Surface Diseases on Monday, May 6, during the Industry Spotlight Theater at the 2019 ASCRS•ASOA Annual Meeting.
Dr. Milner's presentation is part of Industry Spotlight Theater 303: Advancing the Management of Ocular Surface Disease, which is being moderated by Elizabeth Yeu, MD, and will take place Monday, May 6 from 2 – 3 p.m. in Hall C, Booth #1345, at the San Diego Convention Center. Dr. Milner is scheduled to speak on "Cryopreserved Amniotic Membrane to Treat OSD: The Present and Future" at 2:35 p.m.
"The scientific and clinical research on cryopreserved amniotic membrane technology continues to support its use in a multitude of ocular surface conditions," said Dr. Milner. "Bio-Tissue markets the only such technology that has been recognized by the Food and Drug Administration for optimizing wound healing while suppressing inflammation and scarring – allowing Bio-Tissue products to help manage symptoms and rejuvenate the ocular surface of my patients' eyes."
In addition to Dr. Milner's Industry Spotlight presentation, several other physicians will discuss their experience with Bio-Tissue's PROKERA®, AmnioGraft®, and AmnioGuard® cryopreserved amniotic membrane products at Bio-Tissue's booth #523 during the meeting, including:
Saturday, May 4
Attendees will also be able to get a hands-on experience with Bio-Tissue products during wet labs at Bio-Tissue booth #532 during exhibit hours Saturday, May 4 – Monday, May 6. Attendees can also speak with Bio-Tissue representatives during the ASCRS Subspecialty Day, open to all attendees of ASCRS Refractive Day, ASCRS Glaucoma Day, and ASCRS Cornea Day, on Friday, May 3 from 7 a.m.-4 p.m..
About Bio-Tissue, Inc. Bio-Tissue, Inc., a TissueTech, Inc. company, is the market leader in the clinical application of cryopreserved amniotic membrane-based products for the treatment of diseases and disorders of the ocular surface. Established in 1997, Bio-Tissue® serves an unmet need for better surgical and therapeutic alternatives for helping eye care professionals manage ocular surface conditions, such as keratitis, recurrent corneal erosions, conjunctivochalasis, dry eye, pterygium and dry eye.
About TissueTech, Inc. TissueTech, Inc., the parent company of Amniox Medical, Inc. and Bio-Tissue , Inc., pioneered the development and clinical application of amniotic tissue-based products. Amniox Medical develops and markets products for use in the musculoskeletal and wound care markets; Bio-Tissue develops and markets products for the ophthalmology and optometry markets. Since the company's inception, clinicians have performed more than 500,000 human implants of the company's products and published more than 300 peer-reviewed studies supporting its technology platform. The Company's first product, AmnioGraft®, is the only tissue graft designated by the FDA as homologous for promoting ophthalmic wound healing. Learn more at http://www.tissuetech.com.
Disclaimer: The techniques to be presented at ASCRS are for informational purposes only and contain the opinions of and personal techniques practiced by the presenting physician. All educational content of the ASCRS•ASOA Annual Meeting is planned by its program committee, and ASCRS•ASOA does not endorse, promote, approve, or recommend the use of any products, devices, or services.
SOURCE Bio-Tissue, Inc.
Advertisement
Dr. Milner's presentation is part of Industry Spotlight Theater 303: Advancing the Management of Ocular Surface Disease, which is being moderated by Elizabeth Yeu, MD, and will take place Monday, May 6 from 2 – 3 p.m. in Hall C, Booth #1345, at the San Diego Convention Center. Dr. Milner is scheduled to speak on "Cryopreserved Amniotic Membrane to Treat OSD: The Present and Future" at 2:35 p.m.
"The scientific and clinical research on cryopreserved amniotic membrane technology continues to support its use in a multitude of ocular surface conditions," said Dr. Milner. "Bio-Tissue markets the only such technology that has been recognized by the Food and Drug Administration for optimizing wound healing while suppressing inflammation and scarring – allowing Bio-Tissue products to help manage symptoms and rejuvenate the ocular surface of my patients' eyes."
In addition to Dr. Milner's Industry Spotlight presentation, several other physicians will discuss their experience with Bio-Tissue's PROKERA®, AmnioGraft®, and AmnioGuard® cryopreserved amniotic membrane products at Bio-Tissue's booth #523 during the meeting, including:
Saturday, May 4
- 9:30-10 a.m.: Dr. Neel Desai will present on the Reservoir Restoration Technique for Conjunctivochalasis: A Solution for Mechanically-Induced Dry Eye
- 2:30-3 p.m.: Dr. John Sheppard will present on Optimizing the Ocular Surface Prior to Cataract Surgery: Superficial Keratectomy + PROKERA
- 10-10:30 a.m.: Dr. Marjan Farid will present on Healing for PED, Ulcers, RCE, and NK with PROKERA
- 12-12:30 p.m.: Dr. Thomas John will present on Corneal Nerve Regeneration Utilizing Self-Retained Cryopreserved Amniotic Membrane
- 9:30-10 a.m.: Dr. Neel Desai will present on the TissueTuck Technique for Pterygium Surgery: Minimize Recurrence, Optimize Outcomes, and Save OR Time
Attendees will also be able to get a hands-on experience with Bio-Tissue products during wet labs at Bio-Tissue booth #532 during exhibit hours Saturday, May 4 – Monday, May 6. Attendees can also speak with Bio-Tissue representatives during the ASCRS Subspecialty Day, open to all attendees of ASCRS Refractive Day, ASCRS Glaucoma Day, and ASCRS Cornea Day, on Friday, May 3 from 7 a.m.-4 p.m..
About Bio-Tissue, Inc. Bio-Tissue, Inc., a TissueTech, Inc. company, is the market leader in the clinical application of cryopreserved amniotic membrane-based products for the treatment of diseases and disorders of the ocular surface. Established in 1997, Bio-Tissue® serves an unmet need for better surgical and therapeutic alternatives for helping eye care professionals manage ocular surface conditions, such as keratitis, recurrent corneal erosions, conjunctivochalasis, dry eye, pterygium and dry eye.
About TissueTech, Inc. TissueTech, Inc., the parent company of Amniox Medical, Inc. and Bio-Tissue , Inc., pioneered the development and clinical application of amniotic tissue-based products. Amniox Medical develops and markets products for use in the musculoskeletal and wound care markets; Bio-Tissue develops and markets products for the ophthalmology and optometry markets. Since the company's inception, clinicians have performed more than 500,000 human implants of the company's products and published more than 300 peer-reviewed studies supporting its technology platform. The Company's first product, AmnioGraft®, is the only tissue graft designated by the FDA as homologous for promoting ophthalmic wound healing. Learn more at http://www.tissuetech.com.
Disclaimer: The techniques to be presented at ASCRS are for informational purposes only and contain the opinions of and personal techniques practiced by the presenting physician. All educational content of the ASCRS•ASOA Annual Meeting is planned by its program committee, and ASCRS•ASOA does not endorse, promote, approve, or recommend the use of any products, devices, or services.
SOURCE Bio-Tissue, Inc.
